Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964448 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL4964447 | 1.00 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5161815 | 0.69 | GRM8 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL30369747 | 0.68 | SMN1; SMN2 (0.36) | DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL8043620 | 0.61 | SLC7A5 (0.55) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL215360 | 0.61 | — | — | |
| SCHEMBL9227569 | 0.61 | — | — | |
| SCHEMBL20629534 | 0.61 | — | — | |
| SCHEMBL21345145 | 0.61 | — | — | |
| SCHEMBL8313066 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2191824-B1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | KOWALSKI JAMES | 2011-04-14 | — | — | US | disclosed |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | KOWALSKI JAMES | 2010-01-28 | — | — | US | disclosed |
| EP-1898904-B1 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | MAST1, CACNG1, CMA1 | DPP4 267/4885DPP8 1048/4885DPP9 849/4885 |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | MAST1, CMA1, SUCNR1 | DPP4 195/4885DPP8 907/4885DPP9 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.